Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab

Rebecca L. Elstrom, Jia Ruan, Paul J. Christos, Peter Martin, Daniel Lebovic, Joseph Osborne, Stanley Goldsmith, June Greenberg, Richard R. Furman, Anca Avram, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent Griffith, Morton Coleman, John P. Leonard, Mark S. Kaminski

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. We hypothesized that administration of bortezomib as a radiosensitizer with RIT would be tolerable and improve efficacy in NHL. This phase 1 dose-escalation study evaluated escalating doses of bortezomib combined with 131I-tositumomab in patients with relapsed/refractory NHL. Twenty-five patients were treated. Treatment was well tolerated, with primarily hematologic toxicity. The maximum tolerated dose (MTD) was determined to be 0.9 mg/m2 bortezomib, in combination with a standard dose of 75 cGy 131I-tositumomab. Sixteen patients responded (64%), including 44% complete responses (CRs), with 82% CR in patients with follicular lymphoma (FL). At a median follow-up of 7 months, median progression-free survival was 7 months, and seven of 11 patients with FL remained in remission at a median of 22 months. In conclusion, bortezomib can be safely administered in combination with 131I-tositumomab with promising response rates.

Original languageEnglish
Pages (from-to)342-346
Number of pages5
JournalLeukemia and Lymphoma
Volume56
Issue number2
DOIs
StatePublished - 1 Feb 2015
Externally publishedYes

Keywords

  • Lymphoma
  • Proteasome
  • Radioimmunotherapy
  • Radiosensitization

Fingerprint

Dive into the research topics of 'Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab'. Together they form a unique fingerprint.

Cite this